拥抱伊马替尼：一种保护新冠肺炎患者内皮屏障的新方法。

IF 9.2 1区医学 Q1 PERIPHERAL VASCULAR DISEASE Angiogenesis Pub Date : 2023-08-02 DOI:10.1007/s10456-023-09889-2

Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan

{"title":"拥抱伊马替尼：一种保护新冠肺炎患者内皮屏障的新方法。","authors":"Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan","doi":"10.1007/s10456-023-09889-2","DOIUrl":null,"url":null,"abstract":"<div><p>Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-κB signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID.</p></div>","PeriodicalId":7886,"journal":{"name":"Angiogenesis","volume":"26 4","pages":"481 - 483"},"PeriodicalIF":9.2000,"publicationDate":"2023-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19\",\"authors\":\"Chia Siang Kow, Dinesh Sangarran Ramachandram, Syed Shahzad Hasan\",\"doi\":\"10.1007/s10456-023-09889-2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-κB signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID.</p></div>\",\"PeriodicalId\":7886,\"journal\":{\"name\":\"Angiogenesis\",\"volume\":\"26 4\",\"pages\":\"481 - 483\"},\"PeriodicalIF\":9.2000,\"publicationDate\":\"2023-08-02\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Angiogenesis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://link.springer.com/article/10.1007/s10456-023-09889-2\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Angiogenesis","FirstCategoryId":"3","ListUrlMain":"https://link.springer.com/article/10.1007/s10456-023-09889-2","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

摘要

伊马替尼是一种ABL酪氨酸激酶抑制剂，有望恢复新冠肺炎患者的内皮屏障功能，从而防止细胞因子从肺泡室泄漏到全身室。新冠肺炎的特征是肺泡细胞因子风暴，伊马替尼已被证明通过调节NF-κB信号增强内皮屏障并减轻肺泡炎症反应。将伊马替尼纳入新冠肺炎治疗策略提供了一种新的方法来保护内皮屏障并解决该疾病的复杂病理生理学，包括其对长期COVID的潜在影响。鉴于内皮功能障碍在新冠肺炎进展和长期新冠肺炎发展中起着核心作用，在急性感染期间保护内皮屏障对于预防与长期新冠病毒相关的持续内皮功能障碍至关重要。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

Embracing Imatinib: a novel approach to safeguarding the endothelial barrier in patients with COVID-19

Imatinib, an ABL tyrosine-kinase inhibitor, shows promise in restoring endothelial barrier function in patients with COVID-19, thus, preventing cytokine leakage from the alveolar compartment to the systemic compartment. COVID-19 is characterized by an alveolar cytokine storm, and imatinib has been shown to strengthen the endothelial barrier and mitigate alveolar inflammatory responses by modulating NF-κB signaling. Incorporating imatinib into COVID-19 treatment strategies offers a novel approach to safeguard the endothelial barrier and address the complex pathophysiology of the disease, including its potential implications in long COVID. Given that endothelial dysfunction plays a central role in COVID-19 progression and long COVID development, protecting the endothelial barrier during acute infection is crucial in preventing the persistent endothelial dysfunction associated with long COVID.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Angiogenesis PERIPHERAL VASCULAR DISEASE-

CiteScore

21.90

自引率

8.20%

发文量

审稿时长

6-12 weeks

期刊介绍： Angiogenesis, a renowned international journal, seeks to publish high-quality original articles and reviews on the cellular and molecular mechanisms governing angiogenesis in both normal and pathological conditions. By serving as a primary platform for swift communication within the field of angiogenesis research, this multidisciplinary journal showcases pioneering experimental studies utilizing molecular techniques, in vitro methods, animal models, and clinical investigations into angiogenic diseases. Furthermore, Angiogenesis sheds light on cutting-edge therapeutic strategies for promoting or inhibiting angiogenesis, while also highlighting fresh markers and techniques for disease diagnosis and prognosis.